The extensions referred to in point (a) of the first paragraph shall be examined in accordance with the procedure referred to in Article 17 of Directive 2001/83/EC and in Article 21 of Directive 2001/82/EC.
Article 4 Notification procedure for minor variations type IA 1.
Each competent authority concerned shall, where necessary, update the marketing authorisation, which has been granted pursuant to Article 6 of Directive 2001/83/EC or Article 5 of Directive 2001/82/EC.
Article 5 Notification procedure for minor variations type IB 1.
If the notification fulfils the requirements set out in paragraphs 1 to 4, the competent authority of the reference Member State shall acknowledge receipt of a valid notification and shall start the procedure set out in paragraphs 6 to 11. 6.
Each competent authority concerned shall, where necessary, update the marketing authorisation which has been granted pursuant to Article 6 of Directive 2001/83/EC or Article 5 of Directive 2001/82/EC. 8.
The competent authority of the reference Member State shall forthwith inform the holder and the other competent authorities concerned accordingly. 11.
Article 6 Approval procedure for major variations type II 1.
With regard to major variations of type II, the holder shall submit simultaneously to the competent authorities of the Member States where the medicinal product has been authorised an application accompanied by: (a) the relevant particulars and supporting documents referred to in Articles 8 to 12 of Directive 2001/83/EC or Articles 12 to 15 of Directive 2001/82/EC; (b) the supporting data relating to the variation applied for; (c) all documents amended as a result of the application; (d) an addendum to or update of existing expert reports/overviews/summaries to take account of the variation applied for; (e) a list of the Member States concerned by the application for the major variation type II and an indication of the reference Member State for the medicinal product under consideration; (f) the relevant fees provided for in the applicable national rules in the Member States concerned. 2.
The competent authority of the reference Member State shall inform the other competent authorities of the Member States concerned and the holder of the date of the start of the procedure set out in paragraphs 7 to 13. 7.
In this case the periods laid down in paragraph 7 may be extended for a further period to be determined by the competent authority of the reference Member State.
The competent authority of the reference Member State shall inform the other competent authorities concerned. 9.
Each competent authority concerned shall, where necessary, amend the marketing authorisation concerned which has been granted pursuant to Article 6 of Directive 2001/83/EC or Article 5 of Directive 2001/82/EC in conformity with the draft decision referred to paragraph 9. 11.
Article 7 Human influenza vaccines 1.
Within 30 days following the date of the start of the procedure, the competent authority of the reference Member State shall prepare an assessment report on the basis of the quality documents referred to in Module 3 of Annex I to Directive 2001/83/EC and a draft decision which shall be addressed to the other competent authorities concerned. 3.
It shall inform the other competent authorities of the Member States concerned. 4.
Within 12 days of receipt of the draft decision and the assessment report, the other competent authorities of the Member States concerned shall recognise the draft decision and inform the competent authority of the reference Member State to this effect. 5.
The other competent authorities concerned shall recognise the final draft decision and, within 7 days of the receipt of the draft final decision, adopt a decision in conformity with the final draft decision. 6.
Article 8 Pandemic situation with respect to human diseases In case of a pandemic situation with respect to the human influenza virus, duly recognised by the World Health Organisation or by the Community in the framework of Decision No 2119/98/EC of the European Parliament and of the Council(8), competent authorities may exceptionally and temporarily consider the variation to the terms of the marketing authorisation for human influenza vaccines to be accepted after an application has been received and before the end of the procedure laid down in Article 7.
The corresponding variation application reflecting the urgent safety restriction shall be submitted immediately and in any case not later than 15 days after the initiation of the urgent safety restriction, to the competent authorities for the application of the procedures set out in Article 6. 2.
This paragraph is without prejudice to Article 36 of Directive 2001/83/EC and Article 40 of Directive 2001/82/EC.
Article 10 Repeal Regulation (EC) No 541/95 is repealed.
Article 11 This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Done at Brussels, 3 June 2003.
For the Commission Erkki Liikanen Member of the Commission (1) OJ L 311, 28.11.2001, p. 67. (2) OJ L 311, 28.11.2001, p. 1. (3) OJ L 55, 11.3.1995, p. 7. (4) OJ L 159, 3.6.1998, p. 31. (5) OJ L 15, 17.1.1987, p. 38. (6) OJ L 214, 24.8.1993, p. 40. (7) OJ L 224, 18.8.1990, p. 1. (8) OJ L 268, 3.10.1998, p. 1.
ANNEX I LIST AND CONDITIONS FOR MINOR VARIATIONS (TYPE IA AND IB) TO A MARKETING AUTHORISATION AS REFERRED TO IN ARTICLES 3 TO 5 Introductory statements The titles of the variations are numbered and subcategories depicted by letters and numbers in smaller font.
The Commission, in consultation with member states, the Agency and interested parties, will draw up and publish detailed guidance on the documentation to be submitted. %gt%TABLE%gt% (1) OJ L 214, 24.8.1993, p. 1. (2) Food and food ingredients compliant with Regulation (EC) No 258/97 of the European Parliament and the Council (OJ L 43, 14.2.1997, p. 1), colours for use in foodstuffs within the scope of Council Directive 94/36/EC (OJ L 237, 10.9.1994, p. 13), food additives within the scope of Council Directive 88/388/EEC (OJ L 184, 15.7.1988, p. 61), extraction solvents within the meaning of Council Directive 88/344/EEC (OJ L 157, 24.6.1988, p. 28) as last amended by Directive 92/115/EEC (OJ L 409, 31.12.1992, p. 31) and foods or food ingredients derived from a biotechnology step which has been introduced into the manufacturing/production are not required to be notified as a variation to the terms of the marketing authorisation.
